123653-11-2 Usage
Uses
Used in Pharmaceutical Industry:
NS-398 is used as a selective Cox-2 inhibitor for its neuroprotective properties. It is particularly effective in modulating the inflammatory response and has potential applications in the treatment of various conditions associated with COX-2 overexpression, such as pain, inflammation, and neurodegenerative diseases.
Used in Research Applications:
In the field of research, NS-398 is used as a valuable tool for studying the role of COX-2 in various biological processes and disease mechanisms. It helps researchers understand the molecular pathways involved in inflammation and pain, as well as the potential therapeutic targets for developing new drugs.
Used in Drug Development:
NS-398 serves as a starting point for the development of new drugs targeting COX-2, which may have improved selectivity, potency, and reduced side effects compared to existing COX-2 inhibitors. This can lead to the development of more effective treatments for conditions where COX-2 plays a significant role, such as arthritis, Alzheimer's disease, and cancer.
Biological Activity
Selective cyclooxygenase-2 inhibitor (IC 50 values are 3.8 and > 100 μ M for COX-2 and COX-1 respectively). Induces apoptosis in colorectal tumor cells and elevates COX-2 protein expression in vitro . Orally active and non-ulcerogenic analgesic and anti-inflammatory in vivo .
references
[1]. futaki n, takahashi s, yokoyama m, et al. ns-398, a new anti-inflammatory agent, selectively inhibits prostaglandin g/h synthase/cyclooxygenase (cox-2) activity in vitro. prostaglandins, 1994, 47(1): 55-59.[2]. elder dj, halton de, crew te, et al. apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug ns-398. int j cancer, 2000, 86(4): 553-560.[3]. mack strong ve, mackrell pj, concannon em, et al. ns-398 treatment after trauma modifies nf-kappab activation and improves survival. j surg res, 2001, 98(1): 40-46.
Check Digit Verification of cas no
The CAS Registry Mumber 123653-11-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,3,6,5 and 3 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 123653-11:
(8*1)+(7*2)+(6*3)+(5*6)+(4*5)+(3*3)+(2*1)+(1*1)=102
102 % 10 = 2
So 123653-11-2 is a valid CAS Registry Number.
InChI:InChI=1/C13H18N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h7-9,11,14H,2-6H2,1H3
123653-11-2Relevant academic research and scientific papers
Synthesis of carbon-11 labeled sulfonanilide analogues as new potential PET agents for imaging of aromatase in breast cancer
Wang, Min,Lacy, Gabrielle,Gao, Mingzhang,Miller, Kathy D.,Sledge, George W.,Zheng, Qi-Huang
, p. 332 - 336 (2007/10/03)
Aromatase is a particularly good target in the treatment of estrogen receptor positive breast cancer. Novel carbon-11 labeled sulfonanilide analogues, N-[11C]methyl-N-(2-alkyloxy-4-nitrophenyl)-methanesulfonamide s ([11C]3a-f, alkyl
SULFONANILIDE ANALOGS AS SELECTIVE AROMATASE MODULATORS
-
, (2010/11/28)
Compounds and methods suppressing aromatase activity expression in cancer cells. Provided are compounds are those of formula I: wherein R1 may be alkyl, cycloakyl, haloalkyl, aryl, substituted aryl, haloaryl, alkoxy, alkylaryl, and arylalkyl; R2 is H, alk
Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition
Su, Bin,Diaz-Cruz, Edgar S.,Landini, Serena,Brueggemeier, Robert W.
, p. 1413 - 1419 (2007/10/03)
Aromatase is a particularly attractive target in the treatment of estrogen receptor positive breast cancer. Aromatase levels in breast cancer cells are enhanced by prostaglandins and reduced by COX inhibitors. The synthesis and biological evaluation of a
Method for the treatment and prevention of cachexia
-
, (2008/06/13)
Cachexia, including anorexia and other forms of weight loss, is a frequent complication of acute and chronic infections, and result from induction of cytokines, prostaglandins, and other inflammatory mediators that are critical for pathogen elimination. The present invention includes methods for the treatment or prevention of cachexic conditions while maintaining the production of factors essential for infection control through the administration of an effective amount of a cyclooxygenase-2 selective inhibiting compound.
Antiangiogenic combination therapy for the treatment of cancer
-
, (2008/06/13)
The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.
Sulfonanilide compounds
-
, (2008/06/13)
Sulfonanilide compounds represented by the formula STR1 wherein R1 is a lower alkyl group or a trifluoromethyl group, R2 is a cycloalkylidenemethyl group, a group of the formula --A--R3 (wherein A is an oxygen atom, a sulf
